New vaccine aims to stop myeloma from coming back
NCT ID NCT06435910
First seen Apr 26, 2026 · Last updated Jun 10, 2026 · Updated 6 times
Summary
This early-stage trial tests a personalized vaccine made from a patient's own immune cells (dendritic cells) to keep multiple myeloma or plasmacytoma in remission. The study includes 10 patients who have already achieved very good partial or complete remission after other treatments. The main goal is to check safety, and also to see if the vaccine can boost the immune system to fight remaining cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA OR PLASMACYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health
RECRUITINGVladivostok, 690105, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.